Regional differences in the management and outcome of kidney transplantation in patients with human immunodeficiency virus infection: A 3‐year retrospective cohort study

Cristelli, Marina Pontello; Cofan, Frederic; Tedesco‐Silva, Hélio; Trullàs, Joan Carles; Santos, Daniel Wagner; Manzardo, Christian; Agüero, Fernando; Moreno, Asunción; Oppenheimer, Federico; Diekmann, Fritz; Medina‐Pestana, José Osmar; Miró, José M.

doi:10.1111/tid.12724

Cited by 4 publications

(2 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite initial concern, HIV+ kidney and liver transplantation series in the US and Europe show low rates of OIs(Table 1). For example, only 6 cases each of pneumocystis and Kaposi's sarcoma were reported in over 1000 recipients, despite variable ATG use (0-100%) and 1-year rejection (8-47%) (37,39,43,49,50,(88)(89)(90)(91)(92)(93)(94)(95). Cytomegalovirus (CMV) viremia has been reported in up to 25% of HIV+ recipients, yet tissue-invasive disease was <5% across series (89,90,93).…”

Section: Infection Risk Following Hiv+ Sotmentioning

confidence: 99%

Solid Organ Transplantation in HIV-Infected Recipients: History, Progress, and Frontiers

Werbel

Durand

2019

Curr HIV/AIDS Rep

View full text Add to dashboard Cite

a) Purpose of review: What Is the goal of your paper? What questions did you seek to answer-End-stage organ disease prevalence is increasing among HIV-infected (HIV+) individuals. Trial and registry data confirm that solid organ transplantation (SOT) is efficacious in this population. Optimizing access to transplant and decreasing complications represent active frontiers. b) Recent findings: Summarize the latest research on your topic.-HIV+ recipients historically experienced 2-4 fold higher rejection. Integrase strand transferase inhibitors (INSTIs) minimize drug-interactions and may reduce rejection along with lymphodepleting induction immunosuppression. Hepatitis C virus (HCV) coinfection has been associated with inferior outcomes, yet direct-acting antivirals (DAAs) may mitigate this. Experience in South Africa and the US HIV Organ Policy Equity (HOPE) Act support HIV+ donor to HIV+ recipient (HIV D+/R +) transplantation. c) Summary: What answers did you find? What are the major takeaways/ conclusions of your examination? What's the impact on future research?-SOT is the optimal treatment for end-stage organ disease in HIV+ individuals. Recent advances include use of INSTIs and DAAs in transplant recipients, however strategies to improve access to transplant are needed. HIV D+/R+ transplantation is under investigation and may improve access and provide insights for HIV cure and pathogenesis research.

show abstract

Section: Infection Risk Following Hiv+ Sotmentioning

confidence: 99%

Solid Organ Transplantation in HIV-Infected Recipients: History, Progress, and Frontiers

Werbel

Durand

2019

Curr HIV/AIDS Rep

View full text Add to dashboard Cite

show abstract

“…24 It should be emphasized, however, that earlier studies, including the NIH-sponsored trial by Stock et al, included recipients who received a variety of induction regimens including ATG and still reported very few cases of PCP. 17,19,[25][26][27][28][29][30][31] recipients in several Australian centers between 2010 to 2012. They estimated savings of up to $890,000 with 1-year prophylaxis and $766,000 for lifelong prophylaxis in comparison to the cost of treatment.…”

Section: Discussionmentioning

confidence: 99%

Experience with a six‐month regimen of Pneumocystis pneumonia prophylaxis in 122 HIV‐positive kidney transplant recipients

Mejia

Malat

Boyle

et al. 2020

Transplant Infectious Dis

View full text Add to dashboard Cite

Pneumocystis jiroveci remains an important respiratory pathogen in immunocompromised individuals. Historically, without prophylaxis, the incidence of Pneumocystis pneumonia (PCP) in HIV-negative solid organ transplant (SOT) recipients ranged from 5% to 15%. 1-3 PCP results in significant disease burden in SOT recipients, with mortality rates ranging from 5% to 50% depending on the transplanted organ. 4 Trimethoprim-sulfamethoxazole (TMP/SMX) remains the drug of choice for primary prophylaxis. 5 Atovaquone, dapsone, and pentamidine are reasonable alternatives for those with intolerance to TMP/ SMX. Kidney transplant recipients are most at risk for PCP during periods of heightened immunosuppression. This is usually during the first 6 to 12 months after transplant and during treatment for acute rejection. For HIV-negative recipients, the European guidelines recommend at least 4 months of PCP prophylaxis after transplant. 6 The Kidney Disease Improving Global Outcomes recommends 3 to 6 months of routine prophylaxis. 7 With the widespread use of prophylaxis, PCP is almost non-existent in the first year after kidney transplant among HIV-negative recipients. It is now more commonly seen in the second post-transplant year or even more delayed, occurring 6 to 10 years later. 4,[8][9][10] The global incidence of PCP during

show abstract

Infectious disease events in people with HIV receiving kidney transplantation: Analysis of the Swiss HIV Cohort Study and the Swiss Transplant Cohort Study

Kusejko,

Kouyos,

Bernasconi

et al. 2024

BMC Infect Dis

View full text Add to dashboard Cite

Regional differences in the management and outcome of kidney transplantation in patients with human immunodeficiency virus infection: A 3‐year retrospective cohort study

Abstract: Important regional differences exist in the demographics and management of immunosuppression and antiretroviral therapy. These details may influence AR and infectious complications. Non-AIDS infections leading to early mortality in Brazil deserve special attention.

Cited by 4 publications

References 33 publications

Solid Organ Transplantation in HIV-Infected Recipients: History, Progress, and Frontiers

Solid Organ Transplantation in HIV-Infected Recipients: History, Progress, and Frontiers

Experience with a six‐month regimen of Pneumocystis pneumonia prophylaxis in 122 HIV‐positive kidney transplant recipients

Infectious disease events in people with HIV receiving kidney transplantation: Analysis of the Swiss HIV Cohort Study and the Swiss Transplant Cohort Study

Contact Info

Product

Resources

About